Science

PCOS is renamed PMOS, Lancet-backed change follows 14-year global campaign

A condition defined by metabolism stops being branded as cysts

Images

Maddy Mavrikis, from Sydney, was one of 300 readers to share the story of their PCOS – now known as PMOS – diagnoses with Guardian Australia. Photograph: Carly Earl/The Guardian Maddy Mavrikis, from Sydney, was one of 300 readers to share the story of their PCOS – now known as PMOS – diagnoses with Guardian Australia. Photograph: Carly Earl/The Guardian theguardian.com
Mavrikis: ‘The amount of anxiety I have around this particular part of my life has been building since I was 15.’ Photograph: Carly Earl/The Guardian Mavrikis: ‘The amount of anxiety I have around this particular part of my life has been building since I was 15.’ Photograph: Carly Earl/The Guardian theguardian.com
The new name will be fully implemented in the next update to international guidelines for managing the condition. Photograph: megaflopp/Getty Images/iStockphoto The new name will be fully implemented in the next update to international guidelines for managing the condition. Photograph: megaflopp/Getty Images/iStockphoto theguardian.com
Prof Helena Teede, who spearheaded the name change effort. Photograph: Ellen Smith/The Guardian Prof Helena Teede, who spearheaded the name change effort. Photograph: Ellen Smith/The Guardian theguardian.com

A global coalition of medical societies and patient groups has agreed to rename polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS), according to The Guardian. The change was published in The Lancet and announced at the European Congress of Endocrinology in Prague after a 14-year collaboration spanning six continents. PCOS is commonly described as affecting about one in eight women worldwide.

The old name has long pushed both clinicians and patients toward the wrong mental model. “Polycystic” suggests visible cysts and a single-organ problem, even though people can meet diagnostic criteria without ovaries that look “polycystic” on ultrasound, and the ultrasound finding itself reflects eggs in arrested development rather than true cysts, the report notes. That mismatch shows up in the stories patients tell: irregular periods and high androgen levels can prompt a diagnosis, while the absence of “cysts” can delay it, muddy it, or lead to dismissive care. The new label is designed to pull attention toward what patients often experience as the main burden: a multi-system condition involving endocrine disruption and metabolic risk, including insulin resistance and heightened risks linked to diabetes and cardiovascular disease.

Renaming does not, by itself, change diagnostic thresholds or guarantee better treatment, but it changes what gets asked in the exam room and what gets coded in medical records. When the condition is framed as an ovarian abnormality, the default response can narrow to fertility and ultrasound findings; when it is framed as endocrine and metabolic, clinicians are nudged toward earlier screening for insulin resistance and broader long-term risk management. The Guardian reports that insulin resistance affects a large share of patients, and that the campaign was “powered by patient perspectives,” including hundreds of submitted accounts of delayed diagnosis and confusing messaging. In practice, the people who bear the costs of ambiguity are patients who spend years cycling through appointments, tests, and lifestyle advice that may not be anchored to a coherent explanation of what is wrong.

For now, the shift is mostly visible on paper: a new acronym, a Lancet publication, and a congress announcement in Prague. The next test will be whether PMOS becomes the term that general practitioners use when they decide what to investigate first, and what they tell a teenager who arrives with irregular periods and abnormal bloodwork.